Similar pharmacologic opportunities are presented by the combination treatment with traditional cancer therapeutic modalities including radiotherapy (119) and chemotherapy (120), which have been demonstrated to sensitize tumors to CAR T-cell therapy, or molecular antagonists of inhibitory mechanisms that operate in the TME (e.g. IDO or HO-1 inhibitors). The gene discussed is IDO1; the disease is cancer.